InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Monday, 08/09/2021 12:55:13 PM

Monday, August 09, 2021 12:55:13 PM

Post# of 977
The company has dosed the first TP53-mutated AML patient with 622, in combination with azacitidine. In the trial, ~25 patients with newly diagnosed disease will be enrolled, with the primary endpoints of safety and CR rate.